Home › Companies › GOSSAMER BIO INC. › 2023-2024
At GOSSAMER BIO INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 79 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 221 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the Company's named executive officers… — GOSSAMER BIO INC.'s filing reports the proposal as approved, with 74% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: GOSSAMER BIO INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and GOSSAMER BIO INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 6, 2024: 4 items on GOSSAMER BIO INC.’s Form 8-K, filed June 10, 2024: 2 approved · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore GOSSAMER BIO INC. in the interactive database Compare manager voting policies
These tallies are GOSSAMER BIO INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Skye Drynan | 161,240,706 | -- | -- | 933,528 | 28,757,285 | 99.4% | Not verified | — |
| Elect Director: John Quisel, Ph.D., J.D. | 161,260,707 | -- | -- | 913,527 | 28,757,285 | 99.4% | Not verified | — |
| 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 189,741,141 | 1,157,767 | 32,611 | -- | -- | 99.3% | Approved | — |
| 3. The approval, on an advisory basis, of the compensation of the Company's named executive officers | 115,985,182 | 40,356,919 | 5,831,133 | -- | 28,757,285 | 74% | Approved | — |
Source: GOSSAMER BIO INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
Each item below shows how the 79 asset managers that disclosed a GOSSAMER BIO INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: John Quisel, Ph.D., J.D.
GOSSAMER BIO INC.’s own tally for this item (“Elect Director: John Quisel, Ph.D., J.D.”): 161,260,707 for, 913,527 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 28,962,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,928,510 | 0 | 0 | 0 | For |
| Fidelity | 9,958,533 | 0 | 0 | 0 | For |
| Federated Hermes | 3,065,136 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,255,641 | 0 | 0 | 0 | For |
| Charles Schwab | 1,254,359 | 0 | 0 | 0 | For |
| Victory Capital | 768,088 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 535,000 | 0 | 0 | 0 | For |
| John Hancock | 97,988 | 0 | 0 | 0 | For |
| Equitable | 48,392 | 0 | 0 | 0 | For |
| Nationwide | 23,637 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 18,300 | 0 | 0 | 0 | For |
| Russell Investments | 7,086 | 0 | 0 | 0 | For |
| BlackRock | 1,761 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 556 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Skye Drynan
GOSSAMER BIO INC.’s own tally for this item (“Elect Director: Skye Drynan”): 161,240,706 for, 933,528 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 28,962,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,928,510 | 0 | 0 | 0 | For |
| Fidelity | 9,958,533 | 0 | 0 | 0 | For |
| Federated Hermes | 3,065,136 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,255,641 | 0 | 0 | 0 | For |
| Charles Schwab | 1,254,359 | 0 | 0 | 0 | For |
| Victory Capital | 768,088 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 535,000 | 0 | 0 | 0 | For |
| John Hancock | 97,988 | 0 | 0 | 0 | For |
| Equitable | 48,392 | 0 | 0 | 0 | For |
| Nationwide | 23,637 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 18,300 | 0 | 0 | 0 | For |
| Russell Investments | 7,086 | 0 | 0 | 0 | For |
| BlackRock | 1,761 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 556 | 0 | 0 | 0 | For |
Combines 11 wordings of this item as funds reported it.
74% Approved · of votes cast
Description as filed by funds: Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.
GOSSAMER BIO INC.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers”): 115,985,182 for, 40,356,919 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated:”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,928,510 | 0 | 0 | 0 | For |
| Fidelity | 7,889,194 | 2,069,339 | 0 | 0 | Mixed |
| Federated Hermes | 0 | 3,065,136 | 0 | 0 | Against |
| T. Rowe Price | 2,255,641 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,254,359 | 0 | 0 | Against |
| Victory Capital | 0 | 768,088 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 535,000 | 0 | 0 | Against |
| John Hancock | 97,988 | 0 | 0 | 0 | For |
| Equitable | 35,600 | 12,792 | 0 | 0 | Mixed |
| Nationwide | 0 | 23,637 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 18,300 | 0 | 0 | Against |
| Russell Investments | 0 | 7,086 | 0 | 0 | Against |
| BlackRock | 0 | 1,761 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 556 | 0 | 0 | 0 | For |
Fund voting reports, all 14 managers: 21,207,489 for, 7,755,498 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Octagon Capital Advisors LP | 9,187,883 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 8,055,916 | 0 | 0 | 0 | For |
| Fidelity | 7,981,026 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 0 | 6,130,272 | 0 | 0 | Against |
| Samsara BioCapital, LLC | 6,130,268 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 0 | 0 | 5,729,897 | 0 | Abstain |
| HHLR ADVISORS, LTD. | 4,974,041 | 0 | 0 | 0 | For |
| Citadel | 3,555,993 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 3,509,024 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 0 | 3,300,000 | 0 | 0 | Against |
| Corient Private Wealth LLC | 0 | 3,272,070 | 0 | 0 | Against |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 3,151,502 | 0 | 0 | Against |
| Federated Hermes | 0 | 3,065,136 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 0 | 2,978,546 | 0 | 0 | Against |
| T. Rowe Price | 2,887,874 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 0 | 2,583,481 | 0 | 0 | Against |
| Opaleye Management Inc. | 2,565,000 | 0 | 0 | 0 | For |
| BlackRock | 2,476 | 2,320,446 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 2,283,618 | 0 | 0 | Against |
| DAFNA Capital Management LLC | 1,409,262 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 1,372,465 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 1,366,769 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,254,359 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 1,113,674 | 0 | 0 | Against |
| Goldman Sachs | 1,096,512 | 0 | 0 | 0 | For |
Institutional-manager reports, all 69 managers: 52,927,456 for, 39,767,840 against, 5,729,897 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.3% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE YEAR ENDING DECEMBER 31, 2024.
GOSSAMER BIO INC.’s own tally for this item (“2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 189,741,141 for, 1,157,767 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The selection was ratified by the votes indicated:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 28,962,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,928,510 | 0 | 0 | 0 | For |
| Fidelity | 9,958,533 | 0 | 0 | 0 | For |
| Federated Hermes | 3,065,136 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,255,641 | 0 | 0 | 0 | For |
| Charles Schwab | 1,254,359 | 0 | 0 | 0 | For |
| Victory Capital | 768,088 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 535,000 | 0 | 0 | 0 | For |
| John Hancock | 97,988 | 0 | 0 | 0 | For |
| Equitable | 48,392 | 0 | 0 | 0 | For |
| Nationwide | 23,637 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 18,300 | 0 | 0 | 0 | For |
| Russell Investments | 7,086 | 0 | 0 | 0 | For |
| BlackRock | 1,761 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 556 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 226,218,652 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.83% |
| 2 | Fidelity | 4.40% |
| 3 | Federated Hermes | 1.35% |
| 4 | T. Rowe Price | 1.00% |
| 5 | Charles Schwab | 0.55% |
| 6 | Victory Capital | 0.34% |
| 7 | BRIDGEWAY FUNDS INC | 0.24% |
| 8 | John Hancock | 0.04% |
| 9 | Equitable | 0.02% |
| 10 | Nationwide | 0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Octagon Capital Advisors LP | 4.06% |
| 2 | ARCH Venture Management, LLC | 3.56% |
| 3 | Fidelity | 3.53% |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 2.71% |
| 5 | Samsara BioCapital, LLC | 2.71% |
| 6 | Eversept Partners, LP | 2.53% |
| 7 | HHLR ADVISORS, LTD. | 2.20% |
| 8 | Citadel | 1.57% |
| 9 | PLATINUM INVESTMENT MANAGEMENT LTD | 1.55% |
| 10 | 683 Capital Management, LLC | 1.46% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Octagon Capital Advisors LP | 8.65% | 13G |
| Growth Equity Opportunities 18 VGE, LLC | 8.31% | DEF14A |
| BlackRock | 6.12% | 13F |
| FMR LLC | 5.42% | DEF14A |
| Vanguard Group | 5.31% | 13F |
| Faheem Hasnain | 2.92% | DEF14A |
| Millennium Management | 2.87% | 13F |
| Invus Public Equities, L.P. | 2.77% | 13G |
| FMR (Fidelity) | 1.81% | 13F |
| Citadel Advisors | 1.76% | 13F |
Percentages above are of 226,218,652 shares outstanding, as reported by GOSSAMER BIO INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from GOSSAMER BIO INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
GOSSAMER BIO INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “GOSSAMER BIO (GOSS) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/gossamer-bio-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.